Diplomat Provides 2016 Financial Guidance Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Diplomat Pharmacy (DPLO) PT Cut to $14 at Cowen
January 10, 2017 8:58 AM ESTCowen lowered its price target on Diplomat Pharmacy (NYSE: DPLO) to $14.00 (from $18.00) as the company expects 2016 results to come in towards the lower-end of guidance.
Analyst Charles Rhyee commented, "DPLO now expects 2016 results to come in towards the lower-end of guidance. More... More
